{
    "organizations": [],
    "uuid": "332ecb59417dd46f49f4befaaec86f1280035c46",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kura-oncology-announces-new-patent/brief-kura-oncology-announces-new-patent-for-tipifarnib-in-hematologic-malignancies-idUSFWN1S90LF",
    "ord_in_thread": 0,
    "title": "Kura Oncology Announces New Patent For Tipifarnib In Hematologic Malignancies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Kura Oncology Inc:\n* KURA ONCOLOGY ANNOUNCES NEW PATENT FOR TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES\n* KURA ONCOLOGY INC - BIOMARKER-ENRICHED DATA FROM ONGOING PHASE 2 TRIALS OF TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES EXPECTED IN H2 OF 2018\n* KURA ONCOLOGY INC - PATENT EXPANDS PROTECTION FOR TIPIFARNIB IN U.S., PROVIDES EXCLUSIVITY IN CERTAIN CXCL12-EXPRESSING CANCERS TO 2037 ",
    "published": "2018-05-02T19:40:00.000+03:00",
    "crawled": "2018-05-02T14:58:02.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "kura",
        "oncology",
        "inc",
        "kura",
        "oncology",
        "announces",
        "new",
        "patent",
        "tipifarnib",
        "hematologic",
        "malignancy",
        "kura",
        "oncology",
        "inc",
        "data",
        "ongoing",
        "phase",
        "trial",
        "tipifarnib",
        "hematologic",
        "malignancy",
        "expected",
        "h2",
        "kura",
        "oncology",
        "inc",
        "patent",
        "expands",
        "protection",
        "tipifarnib",
        "provides",
        "exclusivity",
        "certain",
        "cancer"
    ]
}